VIR

Vir BiotechnologyC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$16.00

+82.4% vs current

Most likely

Base case

45%

Probability

Target price

$10.50

+19.7% vs current

B-

Bear case

30%

Probability

Target price

$6.00

-31.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This was a post-earnings follow-up run anchored on the May 6, 2026 company release and May 7, 2026 10-Q. The company source confirmed better runway, Astellas close, and several dated pipeline checkpoints, but checked sources did not provide a reliable consensus revenue/EPS comparison and visible post-print analyst revision flow was sparse, so the earnings read-through remains only moderately stronger rather than thesis-changing. With the anchor close at $9.27 on May 7, the market had not yet delivered a decisive re-rating despite improved cash visibility and preserved catalyst density.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-27eventEASL CHD update is the next clean data checkpointHigh impact

Vir said it will present additional Phase 2 SOLSTICE data for tobevibart plus elebsiran in chronic hepatitis delta at the EASL Congress on May 27-30, 2026, after highlighting Week 72 and Week 96 antiviral activity in its Q1 update; this is the nearest meaningful efficacy checkpoint for the lead liver program [#8-K-2026-05-06] [#10-Q-2026-05-07].

2026-06-30catalystQ2 Astellas cash inflow and longer runway reduce financing pressureMedium impact

Q1 results showed $809.3 million of cash, cash equivalents and investments at March 31, 2026, excluding the combined $315 million Astellas upfront payment and equity investment expected in Q2 2026, while management said current plans fund operations into the second half of 2028; that improves balance-sheet durability but is likely only partly incremental because the collaboration has already been disclosed [#8-K-2026-05-06] [#10-Q-2026-05-07].

2026-10-31catalystVIR-5818 response data can test depth of the oncology platformHigh impact

Vir said Phase 1 dose escalation of HER2-targeted VIR-5818 plus pembrolizumab continues and that response data are expected in the second half of 2026, giving investors another oncology readout beyond VIR-5500 while the company builds its masked T-cell engager franchise [#10-Q-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology